139 related articles for article (PubMed ID: 8942490)
1. Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy.
Broekmans FJ; Hompes PG; Heitbrink MA; Netelenbos CC; Roos JC; Falke TM; Schoemaker J
Am J Obstet Gynecol; 1996 Nov; 175(5):1208-16. PubMed ID: 8942490
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
3. Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone.
Perl V; Marquez J; Schally AV; Comaru-Schally AM; Leal G; Zacharias S; Gomez-Lira C
Fertil Steril; 1987 Sep; 48(3):383-9. PubMed ID: 2957235
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
5. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging.
Andreyko JL; Blumenfeld Z; Marshall LA; Monroe SE; Hricak H; Jaffe RB
Am J Obstet Gynecol; 1988 Apr; 158(4):903-10. PubMed ID: 2966587
[TBL] [Abstract][Full Text] [Related]
6. D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas.
Golan A; Bukovsky I; Schneider D; Ron-el R; Herman A; Caspi E
Fertil Steril; 1989 Sep; 52(3):406-11. PubMed ID: 2528476
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
9. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
[TBL] [Abstract][Full Text] [Related]
10. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP
J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
[TBL] [Abstract][Full Text] [Related]
12. Treatment of symptomatic uterine leiomyoma with letrozole.
Gurates B; Parmaksiz C; Kilic G; Celik H; Kumru S; Simsek M
Reprod Biomed Online; 2008 Oct; 17(4):569-74. PubMed ID: 18854113
[TBL] [Abstract][Full Text] [Related]
13. Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH.
van Leusden HA; Dogterom AA
Gynecol Endocrinol; 1988 Mar; 2(1):45-51. PubMed ID: 2972173
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.
Letterie GS; Coddington CC; Winkel CA; Shawker TH; Loriaux DL; Collins RL
Fertil Steril; 1989 Jun; 51(6):951-6. PubMed ID: 2498132
[TBL] [Abstract][Full Text] [Related]
15. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist.
Huang SC; Chou CY; Lin YS; Tsai YC; Hsu KF; Liu CH; Huang KE
Am J Obstet Gynecol; 1997 Aug; 177(2):417-24. PubMed ID: 9290461
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
[TBL] [Abstract][Full Text] [Related]
17. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
Puzigaća Z; Prelević GM; Sretenović Z
Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
[TBL] [Abstract][Full Text] [Related]
18. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
[TBL] [Abstract][Full Text] [Related]
19. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
20. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
Nakamura Y; Yoshimura Y
Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
[No Abstract] [Full Text] [Related]
[Next] [New Search]
